Global Gamma Delta Car T Cells Based Cancer immunotherapy Market To Surpass USD 4 Billion By 2026 Says Kuick Research.
Global Gamma Delta Car T Cells Based Cancer immunotherapy Market To Surpass USD 4 Billion By 2026 Says Kuick Research
Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026 Report Highlights:
- Commercialization Market Potential After Market Launch: > USD 4 Billion
- Insight on Key Drugs In Research & Development
- Adopted Approaches for Gamma Delta T Cell Therapy
- Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight
- Gamma Delta T Cell Cancer Therapy In Clinical Trials: > 15 Therapies
- Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type
- Gamma Delta T Cell Therapy Future Prospects
Report Download
Recently, immunotherapies based on T-cells have become a huge trend in the management of cancer, especially chimeric antigen receptor T-cells. The emergence of CAR T-cell therapy has shown remarkable reemission rates in patients that do not respond to standard treatments. Despite this, these are associated with fatal side effects and have limited efficacy towards solid tumors. To overcome these barriers, research is mainly focused on rare type of T-cells, gamma delta T-cells. Genomic analyses have shown that these occupy only 5% of total T-cells in our body, but have a potential role against cancer.
Vγ9Vδ2 T cells are the largest gamma delta T cell subpopulation in healthy adults. They are naturally occurring cells in the human immune system that are endowed with a tumor recognition mechanism, allowing them to specifically recognize and kill cells under stress, such as cancerous cells, while leaving healthy cells unharmed. In addition, these cells have properties for both innate and adaptive immune systems, enabling them to serve as functional bridge between these two critical systems to impact tumor killing. Owing to their unique biology, these have gained considerable interest among pharmaceutical market which has led to development of novel gamma delta T-cell therapeutics in market.
Presently, no gamma delta T-cell therapy has been approved by regulatory bodies and wide range of them are confined in preclinical and clinical stages. Lava-051 represents one of the most advanced staged drugs which are developed by Lava Therapeutics. LAVA-051 is a Gammabody that targets CD1d-expressing tumors, including multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). Recently in October, 2021 the drug was granted orphan drug designation for the management of chronic lymphocytic leukemia. Apart from this, the company has also developed LAVA-1207 indicated for the management of prostate cancer.
The pipeline for novel gamma delta T-cell therapy is highly crowded and consists of several candidates which are mainly confined to early stages of development. The potential candidates in development include ADI001, INB200, ACE1831, GDX012, TCB002, INB100, and others. Apart from monotherapy, researchers are also validating the role of gamma delta T-cell therapy in combinational therapy. Various clinical trials are ongoing which are evaluating the role of gamma delta T-cell therapy along with immune checkpoint inhibitors, chemotherapy, and radiotherapy. The coming years will see a dominance of combinational therapies owing to its enhanced efficacy and specific towards the cancer cell.
Key players operating in the industry are undergoing various collaborations and partnerships to expand their product portfolio by developing new products. For instance, in September 2021, Twist Bioscience Corporation collaborated with Adicet to accelerate the discovery of gamma delta T cell therapies against five undisclosed targets. Furthermore, Takeda Pharmaceuticals has acquired Gamma delta Therapeutics to accelerate development of allogeneic gamma delta T cell therapies addressing solid tumors. The rising trends and investments in the market are indicating towards brighter future for gamma delta T-cells in cancer therapy. The other players in the market include Acopedia, Takeda Pharma, TC Biopharma, LavaTheraeutics, Kiromic Biopharma and Adapate Therapeutics.
As per report findings, the global gamma delta T-cell therapeutics market is anticipated to grow with high growth rates during forecast period. The market will be mainly driven by the rapid increase in the geriatric population which possesses significant risk of developing cancer. Moreover, the unavailability of effectively curing cancer drugs also demands for the development of targeted therapy which will also boost the market. The utilization of therapy in management of other diseases will also propel the growth of market. Keeping in mind the high adoption rates of novel cancer therapies, it is expected that US will dominate the market for next 5-7 years. In addition to this, high awareness among the population, presence of large biopharmaceutical sector will also propel the growth of market in this region.
Contact:
Neeraj Chawla
Kuick Research
Research Head
+91-9810410366